OBJECTIVES: To conduct pharmacoeconomic evaluation of Levodopa/Carbidopa/Entacapone (LCE) compared to standard therapy in Parkinson disease treatment. Standard therapy was presented by Levodopa and Carbidopa. METHODS: The cost-effectiveness study was carried conducted. Effectiveness was measured in DALYs. Time horizont for cost-effectiveness analysis was 2 years. A 3% discount rate was used. 1 EUR = 40 RUB. RESULTS: LCE provided benefits in effectiveness compared to standard therapy. LCE reduced days incapacity index twice from 44 to 21 days. Two year pilot study showed that LCE provided 0,83 DALY, than standard therapy presented 0,5 DALY. Also administration of LCE reduced daily Levodopa dose on 68 mg. Total annual costs for LCE therapy were 158 938 (3 974 EUR) RUB. Standard therapy total costs varied from 129 113 RUB (3 228 EUR) to 145 422 RUB (3 636 EUR) yearly according to disease progression grade. Indirect costs, including GDP losses due to temporary disability and payments for temporary disability, were 14 372 RUB (359 EUR) for LCE and 30 113 RUB (753 EUR) for standard therapy. The cost-effectiveness ratio for LCE was 191 492 RUB (4 787 EUR) per DALY, than for standard therapy it was 258 326 RUB (6 458 EUR) per DALY.  CONCLUSIONS: LCE demonstrates lower cost-effectiveness ratio (191 492 RUB) compared to standard Parkinson disease therapy (258 326 RUB), therefore LCE has an advantage over standard therapy in terms of pharmacoeconomic evaluation.